News and Events

Reduced stage-adjusted follow-up schedule safe for AJCC stages 1B to 2C melanoma patients

9 July 2020

According to this international phase 3 randomised control trial, a reduced stage-adjusted follow-up schedule is an appropriate and safe approach for AJCC stages 1B to 2C melanoma patients after staging with sentinel biopsy in terms of quality of life, patient satisfaction, and disease safety at three years.  It also has significant resource usage benefits for national cancer services.

Neoadjuvant studies in melanoma have promising clinical and biomarker results

4 July 2020

This review analyses neoadjuvant trials  in melanoma, discussing endpoint assessment and highlighting biomarker development. Findings show that recent neoadjuvant studies in melanoma have looked at a swathe of agents with promising clinical and biomarker results. Coordinated efforts are underway to translate these findings to earlier stage disease while prioritizing the evaluation of new strategies in unresectable disease.

Radiation before immunotherapy may prolong lives of patients with melanoma that has spread to the brain

4 July 2020

This study retrospectively analyses patients with surgically removed melanoma brain metastases who underwent treatment with either radiation, immunotherapy or a combination of both between 2010 and 2018. Results showed the combination of radiation therapy and immune checkpoint inhibitors correlated to better patient survival when compared to radiation therapy alone. More specifically radiation followed by immunotherapy was superior compared to immunotherapy followed by radiation therapy.

Long-term outcomes after treatment discontinuation of anti–PD-1 therapy

3 July 2020

The purpose of this study was to analyze long-term outcomes after treatment discontinuation of anti–programmed death-1 (anti–PD-1) therapy. The study concludes that most patients discontinued treatment at the time of complete response (CR), and that most CRs were durable but the probability of treatment failure was 27% at 3 years. 

A risk prediction model for the development of subsequent primary melanoma

3 July 2020

To guide skin surveillance, a risk prediction model for subsequent primary melanomas was developed, using demographic, phenotypical, histopathological, sun exposure and genomic risk factors. The study concludes that the risk prediction model and its associated nomograms enable estimation of the absolute risk of subsequent primary melanoma, on the basis of on an individual's risk factors, and can be used to tailor surveillance intensity, communicate risk and provide patient education.